191 related articles for article (PubMed ID: 22526172)
1. [Chemotherapy for bladder cancer: 2012 Update. From AUO ("Arbeitsgemeinschaft Urologische Onkologie") and IABC ("Interdisziplinäre Arbeitsgruppe BlasenCarcinom")].
Heck MM; Gschwend JE; Retz M; ;
Urologe A; 2012 Jun; 51(6):829-36. PubMed ID: 22526172
[TBL] [Abstract][Full Text] [Related]
2. [Short version of the German S3 guideline for bladder cancer].
Retz M; Gschwend JE; Maisch P
Urologe A; 2016 Sep; 55(9):1173-87. PubMed ID: 27495910
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer.
Sternberg CN; Donat SM; Bellmunt J; Millikan RE; Stadler W; De Mulder P; Sherif A; von der Maase H; Tsukamoto T; Soloway MS
Urology; 2007 Jan; 69(1 Suppl):62-79. PubMed ID: 17280909
[TBL] [Abstract][Full Text] [Related]
4. [Clinical trials for bladder cancer in Germany].
Lehmann J; Böhle A
Urologe A; 2005 Dec; 44(12):1435-8. PubMed ID: 16258754
[TBL] [Abstract][Full Text] [Related]
5. [S3 guideline for bladder cancer : Claim and reality - a critical commentary from the guideline coordinators].
Retz M; Maisch P; Gschwend JE
Urologe A; 2016 Sep; 55(9):1188-91. PubMed ID: 27581238
[No Abstract] [Full Text] [Related]
6. Systemic therapy in muscle-invasive and metastatic bladder cancer: current trends and future promises.
Aragon-Ching JB; Trump DL
Future Oncol; 2016 Sep; 12(17):2049-58. PubMed ID: 27306417
[TBL] [Abstract][Full Text] [Related]
7. [Combined chemohormonal therapy for metastatic hormone-sensitive prostate cancer : Effectiveness and update as a joint statement by the Study Group on Oncology (AKO) and the Working Group on Urological Oncology (AUO)].
Ohlmann CH; Gschwend J; Miller K;
Urologe A; 2015 Nov; 54(11):1606-8. PubMed ID: 26385244
[No Abstract] [Full Text] [Related]
8. [Systemic chemotherapy for bladder cancer: news in 2009].
Retz M; Gschwend JE; Lehmann J
Urologe A; 2009 Jun; 48(6):655-62. PubMed ID: 19557469
[TBL] [Abstract][Full Text] [Related]
9. [Update on chemotherapy for bladder cancer. Update 2010].
Heck MM; Gschwend JE; Retz M
Urologe A; 2010 Oct; 49(10):1294-300. PubMed ID: 20859610
[TBL] [Abstract][Full Text] [Related]
10. Kuhn's paradigms: are those closest to treating bladder cancer the last to appreciate the paradigm shift?
Bajorin DF; Herr HW
J Clin Oncol; 2011 Jun; 29(16):2135-7. PubMed ID: 21502548
[No Abstract] [Full Text] [Related]
11. [Update of the Clinical Guidelines of the European Association of Urology on muscle-invasive and metastatic bladder carcinoma].
Stenzl A; Cowan NC; De Santis M; Jakse G; Kuczyk MA; Merseburger AS; Ribal MJ; Sherif A; Witjes JA;
Actas Urol Esp; 2010 Jan; 34(1):51-62. PubMed ID: 20223133
[TBL] [Abstract][Full Text] [Related]
12. [First line therapy for locally advanced or metastatic urothelial cancer : A randomized double blind phase III multicenter study on adjuvant nivolumab therapy versus placebo in patients with invasive high-risk urothelial cancer (CheckMate 274)-AB 58/17 of the AUO].
Rexer H; Ohlmann CH; Gschwend J;
Urologe A; 2017 Oct; 56(10):1331-1332. PubMed ID: 28779222
[No Abstract] [Full Text] [Related]
13. [Non-muscle invasive bladder cancer : Current aspects of diagnostics, local therapy options and the update of the 2016 WHO classification].
Karl A; Grimm T; Jokisch F; Gaisa NT; Stief CG
Urologe A; 2016 Sep; 55(9):1247-58. PubMed ID: 27518790
[TBL] [Abstract][Full Text] [Related]
14. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
Babjuk M; Burger M; Zigeuner R; Shariat SF; van Rhijn BW; Compérat E; Sylvester RJ; Kaasinen E; Böhle A; Palou Redorta J; Rouprêt M;
Eur Urol; 2013 Oct; 64(4):639-53. PubMed ID: 23827737
[TBL] [Abstract][Full Text] [Related]
15. Management of bladder cancer: current and emerging strategies.
Agarwal N; Hussain M
Drugs; 2009 Jun; 69(9):1173-87. PubMed ID: 19537835
[TBL] [Abstract][Full Text] [Related]
16. Update of the International Consultation on Urological Diseases on bladder cancer 2018: non-urothelial cancers of the urinary bladder.
Alanee S; Alvarado-Cabrero I; Murugan P; Kumar R; Nepple KG; Paner GP; Patel MI; Raspollini MR; Lopez-Beltran A; Konety BR
World J Urol; 2019 Jan; 37(1):107-114. PubMed ID: 30069580
[TBL] [Abstract][Full Text] [Related]
17. [The Association of Urological Oncology (AOU) German Cancer Society e.V. The competent counterpart for research in Uro-oncology].
Rexer H;
Urologe A; 2005 Apr; 44(4):408-11. PubMed ID: 15765244
[TBL] [Abstract][Full Text] [Related]
18. [French ccAFU guidelines – Update 2018–2020: Bladder cancer].
Rouprêt M; Neuzillet Y; Pignot G; Compérat E; Audenet F; Houédé N; Larré S; Masson-Lecomte A; Colin P; Brunelle S; Xylinas E; Roumiguié M; Méjean A
Prog Urol; 2019 Sep; 28(S1):R48-R80. PubMed ID: 32093463
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant and adjuvant chemotherapy for invasive bladder cancer.
Smith MR; Kantoff PW
Semin Oncol; 1995 Dec; 22(6):625-32. PubMed ID: 8539637
[TBL] [Abstract][Full Text] [Related]
20. ICUD-EAU International Consultation on Bladder Cancer 2012: Chemotherapy for urothelial carcinoma-neoadjuvant and adjuvant settings.
Sternberg CN; Bellmunt J; Sonpavde G; Siefker-Radtke AO; Stadler WM; Bajorin DF; Dreicer R; George DJ; Milowsky MI; Theodorescu D; Vaughn DJ; Galsky MD; Soloway MS; Quinn DI;
Eur Urol; 2013 Jan; 63(1):58-66. PubMed ID: 22917984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
